MA43801A - Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur - Google Patents
Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleurInfo
- Publication number
- MA43801A MA43801A MA043801A MA43801A MA43801A MA 43801 A MA43801 A MA 43801A MA 043801 A MA043801 A MA 043801A MA 43801 A MA43801 A MA 43801A MA 43801 A MA43801 A MA 43801A
- Authority
- MA
- Morocco
- Prior art keywords
- arrestine
- neurokinin
- pain
- beta
- treatment
- Prior art date
Links
- 230000010799 Receptor Interactions Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900635A AU2016900635A0 (en) | 2016-02-23 | Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43801A true MA43801A (fr) | 2018-11-28 |
Family
ID=59684698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043801A MA43801A (fr) | 2016-02-23 | 2017-02-23 | Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200206299A1 (fr) |
| EP (1) | EP3419644A4 (fr) |
| JP (2) | JP2019509277A (fr) |
| AU (1) | AU2017223226A1 (fr) |
| CA (1) | CA3015545A1 (fr) |
| EA (1) | EA038338B1 (fr) |
| MA (1) | MA43801A (fr) |
| MX (1) | MX2018010174A (fr) |
| WO (1) | WO2017143397A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117446A1 (fr) * | 2018-10-22 | 2020-04-30 | Takeda Pharmaceutical Company Limited | Encapsulation de nanoparticules pour cibler des recepteurs couples a la proteine g dans des endosomes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992016547A1 (fr) * | 1991-03-15 | 1992-10-01 | The Children's Medical Center Corporation | Controle des reponses a mediation par recepteurs nk-1 et diagnostiques associees |
| DE60019318T2 (de) * | 1999-09-22 | 2006-03-09 | Canbas Co., Ltd., Numazu | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe |
| ES2552587B1 (es) * | 2014-05-28 | 2017-01-18 | Fundació Hospital Universitari Vall D'hebron-Institut De Recerca | Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes |
-
2017
- 2017-02-23 MA MA043801A patent/MA43801A/fr unknown
- 2017-02-23 US US16/078,202 patent/US20200206299A1/en not_active Abandoned
- 2017-02-23 JP JP2018544105A patent/JP2019509277A/ja active Pending
- 2017-02-23 CA CA3015545A patent/CA3015545A1/fr active Pending
- 2017-02-23 WO PCT/AU2017/050158 patent/WO2017143397A1/fr not_active Ceased
- 2017-02-23 MX MX2018010174A patent/MX2018010174A/es unknown
- 2017-02-23 EA EA201891895A patent/EA038338B1/ru unknown
- 2017-02-23 EP EP17755650.3A patent/EP3419644A4/fr not_active Withdrawn
- 2017-02-23 AU AU2017223226A patent/AU2017223226A1/en not_active Abandoned
-
2022
- 2022-01-19 JP JP2022006489A patent/JP2022064920A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3419644A4 (fr) | 2019-11-13 |
| JP2019509277A (ja) | 2019-04-04 |
| AU2017223226A1 (en) | 2018-08-30 |
| EA038338B1 (ru) | 2021-08-11 |
| CA3015545A1 (fr) | 2017-08-31 |
| MX2018010174A (es) | 2019-01-10 |
| WO2017143397A1 (fr) | 2017-08-31 |
| EP3419644A1 (fr) | 2019-01-02 |
| JP2022064920A (ja) | 2022-04-26 |
| EA201891895A1 (ru) | 2019-02-28 |
| US20200206299A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3340982A4 (fr) | Composés pour le traitement de troubles immunitaires et inflammatoires | |
| EP3019491A4 (fr) | Inhibiteurs de kinase pour le traitement d'une maladie | |
| EP3500267A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs | |
| EP3380200A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3400011A4 (fr) | Combinaisons anti-cd20 pour le traitement des tumeurs | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3380063A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| EP3716966A4 (fr) | Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie | |
| EP3344650A4 (fr) | Aav-epo pour le traitement d'animaux de compagnie | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |